Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765244 | 1.00 | HTR2C (0.51) | HTR2CHTR2AHTR2BSLC9A1GID4 | |
| SCHEMBL318344 | 1.00 | HTR2C (0.51) | HTR2CHTR2AHTR2BSLC9A1GID4 | |
| SCHEMBL318343 | 1.00 | HTR2C (0.51) | HTR2CHTR2AHTR2BSLC9A1GID4 | |
| SCHEMBL9007090 | 0.97 | HTR2C (0.51) | HTR2CHTR2AHTR2BSLC9A1GID4 | |
| SCHEMBL318320 | 0.83 | ALDH1A1 (0.41) | HTR2C | |
| SCHEMBL318321 | 0.83 | ALDH1A1 (0.41) | HTR2C | |
| SCHEMBL318322 | 0.83 | ALDH1A1 (0.41) | HTR2C | |
| SCHEMBL4259949 | 0.81 | HTR2C (0.55) | HTR2CHTR2AHTR2BSLC9A1GID4 | |
| SCHEMBL10263051 | 0.81 | HTR2C (0.55) | HTR2CHTR2AHTR2BSLC9A1GID4 | |
| SCHEMBL757111 | 0.81 | HTR2C (0.55) | HTR2CHTR2AHTR2BSLC9A1GID4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103328451-B | Compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2015-06-10 | — | — | CN | disclosed |
| CN-103328451-A | Compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2013-09-25 | — | — | CN | disclosed |
| US-8211904-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1910364-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1910364-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1853578-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007011833-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006088716-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-0736018-B1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-07-05 | — | — | EP | disclosed |
| US-6025375-A | INHIBITORY ACTIVITY ON PLATELET AGGREGATION, VASODILATING ACTIVITY, ANTIHYPERTENSIVE ACTIVITY OR THE LIKE AND ARE PROSTAGLANDIN I.SUB.2 AGONISTS, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0736018-A1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017393-A1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | HTR2C 356/4885HTR2A 404/4885HTR2B 372/4885 |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | BACE1, APP, PSEN1 | HTR2C 2501/4885HTR2A 1975/4885HTR2B 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.